Amphastar Pharmaceuticals (AMPH) Total Liabilities (2013 - 2026)

Amphastar Pharmaceuticals has reported Total Liabilities for 14 years, with the latest figure at $975.6 million in Q2 2026.

• On a quarterly basis, Total Liabilities rose 13.73% year-over-year to $975.6 million in Q2 2026; TTM through Jun 2026 was $975.6 million, a 13.73% increase from a year earlier, with the FY2025 full-year figure at $840.5 million, down 0.55% from the prior year.
• Total Liabilities was $975.6 million for Q2 2026 at Amphastar Pharmaceuticals, up from $874.8 million in the prior quarter.
• The five-year high for Total Liabilities was $975.6 million in Q2 2026, with the low at $213.3 million in Q4 2022.
• Average Total Liabilities over 5 years is $688.3 million, with a median of $842.8 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Total Liabilities surged 328.61% in 2023, then slipped 13.9% in 2024.
• Over 5 years, Total Liabilities stood at $213.3 million in 2022, then soared by 309.46% to $873.5 million in 2023, then retreated by 3.24% to $845.2 million in 2024, then retreated by 0.55% to $840.5 million in 2025, then rose by 16.08% to $975.6 million in 2026.
• The last three Total Liabilities figures came in at $975.6 million (Q2 2026), $874.8 million (Q1 2026), and $840.5 million (Q4 2025), per Business Quant data.